ProShares Ultra Bloomberg Natural Gas

United States Natural Gas

MicroSectors Gold Miners 3X Leveraged ETN

Altimmune Inc. Common Stock

Direxion Daily Gold Miners Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

ProShares Ultra Silver

Global X Silver Miners ETF

Direxion Daily FTSE China Bull 3X ETF

VanEck Vectors Junior Gold Miners ETF

ProShares UltraShort Bloomberg Natrl Gas

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily Gold Miners Bear 3X ETF

ProShares UltraShort Silver

Bank Of Montreal

Direxion Daily 20+ Yr Trsy Bull 3X ETF

Bank Of Montreal MAX S&P 500 4X Leveraged ETNs due October 30

GraniteShares 1.5x Long NVDA Daily ETF

GraniteShares 2x Long AMZN Daily ETF

BloomZ Inc. Ordinary Shares

Edible Garden AG Incorporated Common Stock

TNL Mediagene Ordinary Shares

Neuraxis Inc. Common Stock

Siyata Mobile Inc. Common Shares

Eyenovia Inc. Common Stock

Click Holdings Limited Ordinary Share

D-Wave Quantum Inc. Common Shares

Warby Parker Inc. Class A Common Stock

Mind Medicine (MindMed) Inc. Common Shares

Protagenic Therapeutics Inc. Common Stock

NWTN Inc. Class B Ordinary Shares

Classover Holdings Inc. Class B Common Stock

Treasure Global Inc. Common Stock

Brainstorm Cell Therapeutics Inc. Common Stock

Theriva Biologics Inc. Common Stock

Luminar Technologies Inc.  Class A Common Stock

Eagle Materials Inc Common Stock

ASP Isotopes Inc. Common Stock

Carter's Inc. Common Stock

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA)  Seeking Alpha

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha

Click here to get full coverage on Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Yahoo Finance

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025  Yahoo Finance

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Yahoo Finance

Click here to get full coverage on Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan

Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial  Stock Titan

Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PR Newswire

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors  PR Newswire

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire - Stock Titan

IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire  Stock Titan

IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma  PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan

IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences  Stock Titan

IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets  PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PR Newswire

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer  PR Newswire

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors  PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024  PR Newswire

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer  PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

Click here to get full coverage on IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC  PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

Click here to get full coverage on IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PR Newswire

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor  PR Newswire

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer - PR Newswire

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer  PR Newswire

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PR Newswire

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance  PR Newswire

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PR Newswire

Click here to get full coverage on Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth? - simplywall.st

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?  simplywall.st

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth? - simplywall.st

Click here to get full coverage on IDEAYA Awards Strategic Stock Options Package: Key Details for New Hires Revealed - Stock Titan

IDEAYA Awards Strategic Stock Options Package: Key Details for New Hires Revealed  Stock Titan

IDEAYA Awards Strategic Stock Options Package: Key Details for New Hires Revealed - Stock Titan

Click here to get full coverage on Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - Yahoo Finance

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation  Yahoo Finance

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development - Stock Titan

IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development  Stock Titan

IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development - Stock Titan

Click here to get full coverage on IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen  PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - PR Newswire

Click here to get full coverage on Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha

Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA)  Seeking Alpha

Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha

Click here to get full coverage on Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus

Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le  GuruFocus

Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus

Click here to get full coverage on IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan

IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout  Stock Titan

IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen - PR Newswire

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen  PR Newswire

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen - PR Newswire

Click here to get full coverage on IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PR Newswire

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma  PR Newswire

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PR Newswire

Click here to get full coverage on Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later  Seeking Alpha

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha

Click here to get full coverage on Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential  Insider Monkey

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

Click here to get full coverage on IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan

IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent  Stock Titan

IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan

Click here to get full coverage on Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus

Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News  GuruFocus

Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus

Click here to get full coverage on IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers  PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - PR Newswire

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium  PR Newswire

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - PR Newswire

Click here to get full coverage on IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer  PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

Click here to get full coverage on Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan

Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors  Stock Titan

Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan

Click here to get full coverage on IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PR Newswire

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024  PR Newswire

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PR Newswire

Click here to get full coverage on IDEAYA Announces Pricing of Public Offering - PR Newswire

IDEAYA Announces Pricing of Public Offering  PR Newswire

IDEAYA Announces Pricing of Public Offering - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors  PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PR Newswire

Click here to get full coverage on Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss - marketscreener.com

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss  marketscreener.com

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss - marketscreener.com

Click here to get full coverage on IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PR Newswire

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor  PR Newswire

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)  PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Click here to get full coverage on All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer - PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer  PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer - PR Newswire

Click here to get full coverage on Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing - Stock Titan

Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing  Stock Titan

Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing - Stock Titan

Click here to get full coverage on Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential  Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - PR Newswire

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events  PR Newswire

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Board Restructuring Plans - TipRanks

IDEAYA Biosciences Announces Board Restructuring Plans  TipRanks

IDEAYA Biosciences Announces Board Restructuring Plans - TipRanks

Click here to get full coverage on IDEAYA Biosciences announces board change and new advisory role - Investing.com

IDEAYA Biosciences announces board change and new advisory role  Investing.com

IDEAYA Biosciences announces board change and new advisory role - Investing.com

Click here to get full coverage on (IDYA) Technical Data - news.stocktradersdaily.com

(IDYA) Technical Data  news.stocktradersdaily.com

Ideaya Biosciences Inc (IDYA)

Price Chart

Key Statistics

Technicals

About IDYA

Latest News

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers